Phreesia (PHR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 May, 2026Executive summary
The annual meeting will be held virtually on June 24, 2026, to elect two Class I directors, ratify the appointment of KPMG LLP as auditor, and hold a non-binding advisory vote on executive compensation.
The board recommends voting in favor of all proposals and emphasizes its commitment to strong governance, diversity, and shareholder engagement.
Only shareholders of record as of May 1, 2026, are entitled to vote; each share has one vote per proposal.
The company provides proxy materials primarily online to reduce environmental impact and costs.
Voting matters and shareholder proposals
Shareholders will vote on electing Chaim Indig and Jon Kessler as Class I directors until 2029.
Ratification of KPMG LLP as independent auditor for fiscal year ending January 31, 2027.
Advisory vote on executive compensation (say-on-pay).
Shareholders may submit proposals for the 2027 meeting by January 14, 2027, and director nominations between February 24 and March 26, 2027.
Board of directors and corporate governance
Board size will reduce from nine to seven directors after the meeting; six of seven will be independent.
Board committees (audit, compensation, nominating/governance) are fully independent.
Board diversity: 71% diverse, with representation by gender and race.
Separate Chair and CEO roles; Ramin Sayar to become Chair after the meeting.
Annual board and committee evaluations, stock ownership guidelines, and NYSE-compliant clawback policy in place.
Latest events from Phreesia
- Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy filing14 May 2026 - FY27 revenue guidance lowered on pharma headwinds, but margin and cash flow outlooks remain strong.PHR
Q4 202630 Mar 2026 - 19% revenue growth, positive free cash flow, and improved EBITDA mark a strong Q2 FY25.PHR
Q2 202522 Jan 2026 - Revenue up 17%, net loss narrowed, and Adjusted EBITDA positive with strong outlooks ahead.PHR
Q3 202511 Jan 2026 - Double-digit revenue growth, positive cash flow, and strong 2026 outlook maintained.PHR
Q4 202526 Dec 2025 - Q3 FY2026 saw 13% revenue growth, profitability, and a major acquisition completed.PHR
Q3 20269 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.PHR
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor ratification, and executive pay approval.PHR
Proxy Filing1 Dec 2025 - Q1 FY2026 revenue up 15%, net loss narrows, EBITDA and free cash flow surge, guidance raised.PHR
Q1 202626 Nov 2025